Apr 8 2010
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Company will be presented with BIOTECanada's Gold Leaf Award as biotech company of the year. The award recognizes a biotech company that has distinguished itself from its peers with strong overall performance as a company, demonstrated leadership and shown significant achievement.
In 2009 OncoGenex announced Phase 2 data from its OGX-011 drug development program, showing a median survival advantage of 6.9 months compared to patients treated only with the current standard of care. The company also confirmed its Phase 3 development plans with the FDA via the Special Protocol Assessment process. In December of 2009, OncoGenex secured a major global partnership with Teva Pharmaceutical Industries to develop and commercialize OGX-011. Following a successful equity financing as well as cash secured through the Teva partnership, OncoGenex closed 2009 with $64.6 million in cash, its strongest cash position in company history.
"2009 was a tremendous year for OncoGenex, and we are honored to be recognized with this esteemed award," said Scott Cormack, president and chief executive officer of OncoGenex. "We are currently focused on a number of accomplishments ahead of us, including initiating Phase 3 clinical trials of OGX-011 in prostate and lung cancer and the advancement of our pipeline programs including OGX-427."
The award will be presented to OncoGenex on May 4 at 4:00pm in the BIOTECanada booth at the BIO 2010 International Convention.
Source:
ONCOGENEX PHARMACEUTICALS, INC.